Description

The CJC 1295 Ipamorelin blend from Pepsynth Labs delivers a highly purified, pre-formulated synergistic combination designed for advanced endocrine and metabolic research. Each vial contains 5mg of CJC-1295 without DAC (Mod GRF 1-29) and 5mg of Ipamorelin, totaling 10mg of active research material. Manufactured in the USA to a rigorous 99% purity standard, this lyophilized compound is engineered to provide laboratory professionals with a precise, multi-layered tool for investigating growth hormone (GH) axis modulation. For alternative formulations, you can browse our full Pepsynth Labs Research Catalog.

Science Behind the CJC 1295 Ipamorelin Blend

In modern research, stimulating the physiological production of GH is mechanistically distinct from the direct administration of synthetic hormones. This specific CJC 1295 Ipamorelin blend capitalizes on a dual-pathway stimulation model, often compared to pressing the accelerator and releasing the brake simultaneously:

• The GHRH Pathway: CJC-1295 without DAC is a synthetic analog based on the first 29 amino acids of growth-hormone-releasing hormone. It binds selectively to GHRH receptors on anterior pituitary somatotrophs, initiating adenylate cyclase activation and promoting the synthesis and release of endogenous GH. Lacking the Drug Affinity Complex (DAC), it features a shorter half-life of approximately 30 minutes, allowing for a more natural, pulsatile pharmacokinetic profile.

• The Ghrelin Pathway: Ipamorelin is a highly selective growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). It functions to trigger the rapid release of stored GH. Crucially, Ipamorelin demonstrates high selectivity for GH release, causing minimal to no clinically relevant elevation in cortisol or prolactin. Learn more about secretagogue mechanisms on the National Institutes of Health (NIH) database.

Because CJC-1295 and Ipamorelin target two distinct pituitary receptor systems, their simultaneous activation produces a synergistic GH pulse that is substantially larger than what either compound can produce alone. .

Technical Specifications

Primary Research Focus Areas of the Peptide Blend

Research involving the combined administration of the CJC 1295 Ipamorelin blend spans several metabolic and cellular repair pathways. Typical laboratory endpoints and observations in these studies include:

• IGF-1 Tracking: Insulin-like growth factor-1 (IGF-1) is the primary downstream effector of pulsatile GH release, making it the standard biomarker for monitoring efficacy and safety in GH-axis research.

• Body Composition & Lipolysis: Investigating how sustained GH elevation promotes lipolysis via hormone-sensitive lipase activation, and enhances muscle protein synthesis through mTOR and PI3K/Akt pathways.

• Tissue Regeneration: Studying the stimulation of satellite cell activation, enhanced collagen synthesis, and accelerated tissue remodeling processes.

• Metabolic Response: Assessing changes in fasting glucose, HbA1c, and fasting insulin to monitor metabolic status, as elevated GH and IGF-1 can act as counter-regulatory hormones that reduce glucose uptake. For data validation, cross-reference your findings with peer-reviewed studies available via PubMed.

Safety & Usage Disclaimer: This product is supplied by Pepsynth Labs strictly for in-vitro laboratory and research use only. It is not approved by the FDA for human consumption, diagnostic, therapeutic, or clinical use. Researchers must handle this compound in accordance with standard safety laboratory protocols.